Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
Bo Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Binlei Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Fuxiang Zhou(Wuhan University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jialin Tang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangyong Gu(Wuhan YZY Biopharma (China)), Chengyun Geng(Chinese Academy of Medical Sciences & Peking Union Medical College), Sheng Hu(Hubei Cancer Hospital), Suxia Luo(Zhengzhou University), Jing Huang(Chinese Academy of Medical Sciences & Peking Union Medical College), Dawei Wu(Chinese PLA General Hospital), Zhiguo Luo(Hubei University of Medicine), Shiyun Tan(Wuhan University), Rui Zhang(Shanghai University of Engineering Science), Qing Chang(Qingdao University)
Cited by 107
Related Papers
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
|Molecular Cancer|2019|1.2k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663